Laduviglusib-d₄  (Synonyms: CHIR-99021-d₄; CT99021-d₄)

Laduviglusib-d₄ (CHIR-99021-d₄) is the deuterium labeled Laduviglusib (HY-10182). Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC₅₀s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy.

1. This compound can be used as a tracer.
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

469.36

C₂₂H₁₄D₄Cl₂N₈

252917-06-9

ClC1=CC=C(C2=C(C=NC(NC([2H])(C([2H])(NC3=CC=C(C=N3)C#N)[2H])[2H])=N2)C4=NC(C)=CN4)C(Cl)=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.